The U.S. National Cancer Institute (NCI) awarded a $144,056 Project Grant under the Cancer Research Manpower Federal Grant Program (CFDA 93.398) to the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The grant supports research to develop computational models that quantitatively predict the impact of clinically observed drug-resistant mutations in cancer-related kinase proteins. This work aims to enhance precision oncology approaches by identifying mutations that confer resistance to kinase inhibitor drugs, as well as potential alternative inhibitors that could overcome such resistance. The project will utilize a combination of binding free-energy calculations, molecular simulations, and high-throughput biophysical experiments to assess how specific mutations affect kinase activity, inhibitor binding, and inhibitor sensitivity. The goal is to build towards a precision oncology platform that can help guide optimal treatment regimens for cancer patients. The award period runs from June 1, 2024 to May 31, 2026.
Generated 1/28/25, 9:18 AM